European Commission approves Gilead's Zydelig for blood cancer

19 September 2014

The European Commission has granted marketing authorization for US biotech major Gilead Sciences’ (Nasdaq: GILD) Zydelig (idelalisib) 150 mg tablets in the treatment of chronic lymphocytic leukemia and follicular lymphoma.

Zydelig inhibits PI3K delta, a protein that is overexpressed in many B-cell malignancies and is active in the viability, proliferation and migration of these cancerous cells.

For chronic lymphocytic leukemia, it has been approved in combination with rituximab for those who have received at least one prior therapy, or as a first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. In follicular lymphoma, it has been approved as a monotherapy in patients who are refractory to two prior lines of treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK